Synexus buys ClinPharm to double patient access
pharmafile | December 8, 2009 | News story | Research and Development |Â Â CRO, SynexusÂ
UK patient recruitment specialist Synexus has boosted its presence in mainland Europe by acquiring German contract research organisation ClinPharm.
The purchase is expected to complete early next year and will increase the number of research centres in the Synexus network to 26, said the site management organisation, which specialises in a ‘hub’ site model that dramatically increases the number of patients it can recruit into trials.
Rather than rely on recruitment by investigators in hospitals, which have many other competing commitments, the company sets up its own centres whose sole function is patient recruitment and the conduct of clinical trials for clients.
ClinPharm, which is based in Leipzig, works to a similar hub-based model and operates 10 centres, including eight sites in Germany, one in Austria and another in Ukraine.
The move is in line with Synexus strategy of expanding into central and eastern Europe (CEE), which has seen the firm open new offices in Hungary, acquire three clinical sites in Poland from local SMO company CLCC and appoint a new vice president for CEE, Dr Christian Tueni, in the last few months.
Synexus currently operates a number of centres in the UK, along with sites in Hungary, Poland and Bulgaria, and also runs two facilities outside of Europe in India and South Africa.
The addition of Germany to its geographic spread is a key development for the company, given that the country is one of the largest pharmaceutical markets in Europe, while Austria helps cement its position in CEE and Ukraine allows it to push even further east into new markets.
The ClinPharm acquisition will increase Synexus’ total patient population reach to over 30 million individuals, which represents an increase of 50% globally and 100% across Europe, according to a Synexus statement.
“No other patient recruitment organisation can compete in terms of size or scale,” it claims.
ClinPharm’s founding chief executive, Dr Hans-Detlev Stahl, will join Synexus as European medical director once the transaction completes. Dr Helena Sigal, currently ClinPharm’s director of operations, will become Synexus’ country manager for Germany.
Related Content
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
From molecule to market and beyond: Uniphar announces extended global commercialization platform
22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service …
Drug development contracts: can lessons be learned from healthcare delivery?
There is a very good question to ask at the beginning of every project: “What …
